China, U.S. Drug Pact Addresses U.S. Security Issues (China)
This article was originally published in PharmAsia News
Executive Summary
U.S. concerns about the safety of drugs imported from China have as much to do with U.S. national security issues as with the safety of the medicines themselves. As an example, China and India are the only sources of key ingredients for two antibiotics considered the only ones suited to treat anthrax if an attack on the U.S. leaves the country short of supplies. The main component of anti-anthrax treatments, doxycycline, is made only in China. But drug-oversight scandals in China, which led to the execution of an official of the State FDA that oversees a $65 billion pharmaceutical industry, are seen as potential problems for the United States. (Click here for more ) "China's Monopoly On Pharmaceuticals Raises U.S., Europe Security Concerns" Taiwan News (12/10/07)
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.